As gene editing technologies like CRISPR progress toward clinical study, researchers must continue to advance new approaches and address inherent challenges, explains Jon Chesnut, PhD, Senior Director, Cell Biology R&D, Thermo Fisher Scientific. Gene editing tools such as zinc finger nucleases, transcription activator-like effector nucleases (TALEN) and clustered regularly interspaced… Read More
DDW highlights the most interesting global news and comments within the drug discovery and development sector this month. Everyone enjoys a good news story and the drug discovery and development sector is no exception. Seeing tangible results of drug efficacy or therapeutics programmes can take years so it was heartening… Read More
The fifth CRISPR in Drug Discovery: From Targets to Therapeutics meeting will be held face to face In Oxford on February 7-8, 2023. The meeting will focus on the application of genome engineering in identification of novel drug targets through large-scale CRISPR based functional genomics studies, developing advanced cellular… Read More
CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect your… Read More
Kevin Holden Join DDW and Synthego for this free exclusive event today at 3pm GMT. Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery. Register now to hear speakers Kevin Holden and… Read More
Kevin Holden In this webinar, hosted by DDW and supported by Synthego, Kevin Holden, Ph.D, Head of Science, Synthego will explain how the company’s engineered cell libraries enable screening more widely and efficiently to increase the pace and impact of target discovery. Join this free exclusive event on 9 November at… Read More
Kevin Holden CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that your organisation may not have. What if you could receive ready-to-use CRISPR-edited cells without needing to handle, optimise, and transfect… Read More
Scientists have shown how stomach cancers can develop resistance to a new class of drugs called ATR inhibitors by switching off the activity of two key genes – raising the possibility of outsmarting cancer by predicting drug resistance in advance. The findings could pave the way for… Read More
Kevin Holden Join this free exclusive event to find out more. It will take place on 9 November at 3pm GMT. CRISPR-based knockouts are the gold-standard genetic perturbation method in target identification and validation. However, efficient CRISPR knockout editing and transfection for arrayed screening require specialised skills and infrastructure that… Read More
News round-up for 10-14 October by DDW Digital Content Editor Diana Spencer The top news in the world of drug discovery this week reflects the vital importance of collaboration, partnership and support within this industry. Partnerships… Read More
A team of researchers at Northwestern University in the US has devised a new platform for gene editing that could inform the future application of CRISPR-based therapeutics. Using chemical design and synthesis, the team brought together the Nobel-prize winning technology with therapeutic technology born in their own lab to overcome… Read More
This paid-for advertorial by Synthego appeared in Volume 23 – Issue 4, Fall 2022. Rise of CRISPR-mediated Therapies After more than two decades of successes and failures, the promise of cell and gene therapy to treat the root cause of many human diseases is now starting to redefine modern medicine. Read More
An international team of researchers has won £30 million for its work in developing a potential cure for inherited heart muscle conditions in young people. CureHeart was selected as the winner of the British Heart Foundation’s (BHF) Big Beat Challenge, which grants a £30 million non-commercial grant… Read More
A one-time treatment for HIV and AIDS may be possible thanks to gene editing, according to research conducted by scientists from Tel Aviv University (TAU). Researchers from Tel Aviv University used CRISPR systems to engineer type B white blood cells into producing HIV-neutralising antibodies in the immune… Read More
Mirus Bio outlines when to use transfection reagents, viral transduction or electroporation No single delivery method is ideal for all situations, but researchers may routinely employ a suboptimal approach for the sake of familiarity or to… Read More
Mirus Bio outlines when to use transfection reagents, viral transduction or electroporation. No single delivery method is ideal for all situations, but researchers may routinely employ a suboptimal approach for the sake of familiarity or to avoid any start-up costs associated with new methods. The uses of… Read More
